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12 months as part of a larger NIH-funded study. The SIS was
administered to this same cohort again at a sixth time point. The
average time since initial stroke to the sixth time point ranged
from 1.6 to 4.04 years, with an average of 2.67 years. RESULTS:
Of the 33 patients, 78.8% were male, 67% had mild stroke, 24%
had moderate stroke, and 9% had severe stroke. The average age
was 68 years (range, 53 to 87 years). A linear mixed model for
repeated measures showed statistically signiﬁcant changes over
time for all subcomponents of the SIS: physical, emotion,
memory and social participation component scores increased
signiﬁcantly (p < 0.001), while communication scores decreased
signiﬁcantly over the same time period (p = 0.02). However, sta-
tistically signiﬁcant decreases in scores were seen between 12
month SIS scores and the additional sixth time point score for
social participation (p = 0.03), memory (p = 0.02), and commu-
nication (p = 0.3). A signiﬁcant increase for this same time period
was demonstrated for emotion (p =< 0.001). CONCLUSION:
Increases in physical, emotion, memory and social participation
component scores demonstrated a signiﬁcant improvement over
an initial 12 month period. However, signiﬁcant decreases in
social participation, memory and communication were seen for
the time period between the 12 month score and scores at least
one and a half to four years later. These results suggest that while
there may be signiﬁcant physical and cognitive improvements
during the ﬁrst year post stroke, individuals were experiencing
difﬁculties with social reintegration, communication and
memory at later time points. Results from this preliminary study
demonstrate the need for continued, longitudinal research on
HRQoL in long-term stroke survivors.
URINARY/KIDNEY—Clinical Outcomes Studies
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OBJECTIVES: The purpose of this study was to assess the effects
of laughter therapy on mood, stress and health-related quality of
life (HRQoL) in patients treated with hemodialysis. METHODS:
This is a randomized controlled intervention study. Brieﬂy, forty
hemodialysis patients attending a university hospital dialysis
center were randomized (1:1) to either a laughter group or a
control group without laughter therapy. A total of 11 patients
completed the laughter therapy program and 18 patients in a
control group were remained. Laughter therapy program was
composed of weekly four group sessions and daily 15 seconds’ of
individual session by telephone for 4 weeks. The mood and stress
were measured by visual analogue scale (VAS) and serum cortisol
level, respectively, and HRQoL was evaluated by kidney disease
quality of life short form version 1.3 (KDQOL-SFTM 1.3) before
and after active laughter program. RESULTS: Mood measured
by VAS was signiﬁcantly improved in the active laughter therapy
group (n = 11) compared to a control group (n = 18) (p < 0.05),
whereas changes in serum cortisol level was not signiﬁcantly
different between two groups. Role due to emotional, social
functioning, and mental health quality of life scales improved
signiﬁcantly in the laughter group (all p’s < 0.05). In the kidney
disease-targeted scales, symptom/problem and quality of social
interaction scales were signiﬁcantly improved in the laughter
group (all p’s < 0.01). CONCLUSION: A Laughter therapy was
an effective program for improving the mood and limitations of
usual role activities due to emotional problems, mental health
and social domains of quality of life in hemodialysis patients.
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OBJECTIVES: Urinary incontinence is a common problem of
women’s health in the developed countries. Tension-free Vaginal
Tape (TVT) and Trans Obturator Tape (TOT) are the most
common minimal-invasive surgical therapy for incontinence
treatment. The aim of our study is to compare the clinical out-
comes of TVT and TOT surgery. METHODS: We randomly
selected 200 women with TVT surgery and 200 women with
TOT surgery (n = 400) from 3 major Hungarian hospitals.
Medical documentation of women underwent TVT or TOT
sugary was analyzed retrospectively focusing on the frequency of
complications, length of hospital stay, reoperation and vaginal
erosion. Statistical analysis was performed by SPSS version 14
and included frequency analysis, conﬁdence interval (CI) and chi
square test. RESULTS: We found signiﬁcantly higher complica-
tion rate at women with TVT surgery compared to TOT method:
bladder injury (1% TVT versus 0.0006), dysuria (21.0% < 0.5%
TOT, p = 0.0183), abdominal pain (30.5% vs. 16.0%, p vs.
13.0%, p = 0.0332), urinary tract infections (13.5% vs. 6.5%,
p = 0.0196), retention (7.5% vs. 2.0%, p = 0.0013), de novo
urge (28.5% vs. 16.5%, p = 0.007). 0.001). In<The average
length of hospital stay was also longer in TVT surgery (p case of
TOT surgery, we found a signiﬁcantly higher reoperation rate
(2% vs. 6.5%, p = 0.0257) and higher rate of vaginal erosion
(0.0% vs. 4%, P = 0.0043). CONCLUSION: Both type of minor
surgical intervention can be considered as efﬁcient way of in-
continence treatment, however TVT surgery is associated with
higher complication rate, longer average hospital stay, therefore
TOT method should be the ﬁrst choice, if applicable.
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OBJECTIVES: End stage renal disease (ESRD) is a debilitating
condition resulting in death unless treated. Data show that two
available therapies, peritoneal-dialysis (PD) and hemodialysis
(HD) have similar survival rates. However, annual average
reimbursements per patient are €18,400 for HD and €12,700 for
PD. Approximately 18% of treated population used PD. The
study estimated the government budget impact of higher PD
reimbursement and the resulting increase in PD utilization.
METHODS: A budget impact model applied a patient-years-
at-risk approach that incorporated point prevalent dialysis
patients, current treatment modality distribution, including
two PD modalities (automated-peritoneal-dialysis or APD and
continuous-ambulatory-peritoneal-dialysis or CAPD), reim-
bursements by modality, annual dialysis population growth rate,
and hypothetical new modality distribution rates. At baseline
(2006), Romania had 7060 treated ESRD patients, patient-years-
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at-risk was set to 0.72, and it was assumed that new dialysis
modality distribution would reach by year 3. The model
allowed various sensitivity analyses. RESULTS: If PD utilization
increased to 25% without any reimbursement increase for PD,
5-year savings was estimated to be €13 million. If APD was
reimbursed by an additional €1300 per patient, 5-year savings
increased to €18 million, assuming overall PD utilization
increased to 30% and APD share of PD increased from 4.5% to
30%. If APD reimbursement increased an additional €2300 per
patient and APD share of PD increased to 50%, it would
require 35% of all PD patients undergoing dialysis treatment to
achieve €18 million savings. Finally, at this level of additional
APD reimbursement, 5-year savings increase to €25 million as
PD utilization increases to 40%. With €25 million in savings, an
additional 1478 patient-years of treatment could be provided in
Romania. CONCLUSION: With additional reimbursement for
PD and the resulting increase in PD utilization, there is an
opportunity for government to lower the total dialysis budget.
Government can apply the savings to treat additional ESRD
patients.
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OBJECTIVES: There is expected to be an increase in the number
of patients needing dialysis in the UK over the next 5 years.
Outcomes for the different modalities available, haemodialysis
(HD) and peritoneal dialysis (PD), have been shown to be similar
yet the majority of dialysis patients are treated with HD. Any
changes in dialysis delivery that could lead to a more efﬁcient use
of resources could increase the number of RRT patients that
could be treated. The objective of this evaluation is to project a
ﬁve-year impact on total dialysis costs when there is a hypoth-
esised shift in modality from HD to PD. METHODS: An Excel-
based budget impact model was used to estimate the impact of a
shift in modality utilisation. The model takes into account dialy-
sis modality shares, annual average cost of treating patients per
modality, annual RRT growth rate and years to reach new
modality distribution. Cost data from a recent UK study were
used. At baseline (June 2007) there were 23,133 RRT patients
undergoing dialysis therapy, 79% using HD and 21% using PD.
Annual direct cost per patient was £39,412 for HD, £20,764
for home HD (HHD), £22,350 for automated PD (APD), and
£16,355 for continuous ambulatory PD (CAPD). Total costs
included drug treatment and transport costs. At baseline, 2% of
the HD population was on HHD and 48% of the PD population
was on CAPD. RESULTS: If PD utilisation increases to 30% (of
which 60% is APD) by 2011, the cumulative 5-year budget is
reduced by a total of £166 million. This cumulative 5-year
savings can provide an additional 5,036 patient-years of treat-
ment. CONCLUSIONS: In the UK, an increased use of PD
provides an opportunity to treat additional patients within a
ﬁxed budget, which is a potential solution to the increased
demand for RRT in the coming years.
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OBJECTIVES: Identiﬁcation of the better drug for immunosup-
pression following renal transplantation. METHODS: Efﬁcacy
data sources included completed comparative randomized clini-
cal trials of Sandimmun Neoral and cyclosporine A generics
(Stolyarevich E. S. 2006, Taber D. J. et al. 2005, CTS 2001); costs
were derived from the wholesale prices of the study drugs
(Protek, Cia International, Shreya Corporation, as of 11 October
2006). The study evaluated the costs of initial and maintenance
immunosuppression, treatment of rejection episodes, and hemo-
dialysis necessitated by transplant death in the compared groups.
RESULTS: Analysis of randomized clinical trials has revealed
that Sandimmun Neoral is superior to cyclosporine A generics as
regards one-year renal graft survival rates (88% vs. 78%) (CTS
2001). Furthermore, application of cyclosporine A generics
entails more frequent episodes of acute rejection (25% vs. 39%),
recurrent rejection (4% vs. 13%), and rejection requiring admin-
istration of antibodies (8% vs. 19%, Taber D. J. et al. 2005). The
total cost of 2-year therapy was over 58.8 million roubles and 72
million roubles per 100 patients in the Sandimmun Neoral and
cyclosporine A generics groups, respectively. CONCLUSION:
Sandimmun Neoral is the leading alternative for immuno-
suppression following renal transplantation, i.e. it is preferable
from a clinicoeconomic perspective.
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OBJECTIVES: Identiﬁcation of the better drug for immunosup-
pression following renal transplantation. METHODS: Efﬁcacy
data sources included completed comparative randomized clini-
cal trials of cyclosporine microemulsion (Sandimmun Neoral,
CsA) and tacrolimus (Prograf, Tac). Costs were derived from the
wholesale prices of the study drugs (international drug distribu-
tor Shreya, as of 25 September 2006). Costs of other medicines
with the exception of calcineurin inhibitors (Mycophenolate
Mofetil, corticosteroids, Azathioprine), transplantation surgery,
diagnostic laboratory procedures, and pharmacokinetic monitor-
ing of blood concentrations of drugs were considered constant
and left out of calculations in this comparative study. RESULTS:
Analysis of randomized clinical trials has revealed similar efﬁca-
cies for both analyzed treatment options, whereas the safety
proﬁle of tacrolimus is more of a problem: the frequency rates of
the new onset post-transplant diabetes mellitus for CsA and Tac
are 26.5% and 33.6%, respectively, according to Vincenti F.
(2005), or 9.8% and 15.4%, respectively, as reported by Keown
P. (2004). The rates of diarrhea in the study of Levy G. (2005)
were 14% in the CsA group and 29% in those treated with Tac.
This study evaluated the costs of initial and maintenance immu-
nosuppression with Sandimmun Neoral and Prograf, which were
approximately 22,600 roubles vs. 58,700 roubles for initial
therapy and 176,300 roubles vs. 952,300 roubles for one-year
maintenance immunosuppression, respectively. The amount of
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